Collaborative frontiers in pediatric neuro-oncology: establishing an international tumor board for enhanced care and global impact

被引:0
作者
Shatara, Margaret [1 ]
Brossier, Nicole M. [2 ]
Cluster, Andrew [2 ]
Mian, Ali Y. [3 ]
Dahiya, Sonika [4 ]
Armstrong, Amy E. [2 ]
Hirbe, Angela C. [5 ]
Gutmann, David H. [6 ]
Aldape, Kenneth [7 ]
Abdelbaki, Mohamed S. [2 ]
机构
[1] Childrens Hosp & Clin Minnesota, Dept Pediat Hematol & Oncol, Pediat Neurooncol Program, Minneapolis, MN 55404 USA
[2] Washington Univ, Sch Med, St Louis Childrens Hosp, Dept Pediat, St Louis, MO USA
[3] Washington Univ, Dept Pathol & Immunol, St Louis, MO USA
[4] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA
[5] Washington Univ, Sch Med, Dept Med, St Louis, MO USA
[6] Washington Univ, Sch Med, Dept Neurol, St Louis, MO USA
[7] NCI, Lab Pathol, Ctr Canc Res, NIH, Bethesda, MD USA
关键词
Pediatric neuro-oncology; CNS tumors; International collaboration; Telemedicine; Global health disparities; CHILDHOOD-CANCER; CHILDREN; BURDEN;
D O I
10.1007/s10147-025-02793-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundCentral nervous system tumors are the leading cause of cancer-related mortality in children, with significant disparities in diagnostic and treatment capabilities between low- and middle-income countries and high-income countries. This study outlines the establishment of an international neuro-oncology tumor board to address these gaps.MethodsThe tumor board was initiated in January 2021 through a partnership between Washington University in St. Louis, USA, and nine institutions, ultimately expanding to 39 institutions across 25 countries. Monthly virtual meetings facilitated multi-disciplinary case reviews offering diagnostic and management recommendations. A retrospective analysis of 29 sessions over three years was conducted, and a cross-sectional web-based survey among participants assessed their experiences and satisfaction.ResultsFrom January 2021 to December 2023, 101 cases were reviewed. The most diagnoses were low-grade gliomas (23.4%) and neurofibromatosis type 1 and 2 (32.7%). Newly diagnosed cases comprised 51%, while 40% involved recurrent or progressive disease, and 9% were inquiries during ongoing therapy. Recommendations predominantly addressed therapeutic strategies (60.7%). Advanced diagnostics, such as methylation profiling, refined diagnoses in several cases. The survey, with a 35% response rate, showed high satisfaction, with 91% finding the meetings educational. Barriers included time constraints (71%) and conflicting commitments (27%).ConclusionThis initiative, to our knowledge, represents the largest international pediatric neuro-oncology tumor board. Multidisciplinary discussions improved diagnostic precision, informed therapeutic decision-making and facilitated educational exchange. Participants reported positive impacts on professional development and alignment with institutional needs. Despite challenges, this study highlights telemedicine's potential to bridge resource disparities and improve the outcomes globally.
引用
收藏
页码:1659 / 1669
页数:11
相关论文
共 26 条
[1]   The Latin American Brain Tumor Board teleconference: results of a web-based survey to evaluate participant experience utilizing this resource [J].
Abu Arja, Mohammad H. ;
Stanek, Joseph R. ;
Morales La Madrid, Andres E. ;
Lassaletta, Alvaro ;
Bartels, Ute ;
Qaddoumi, Ibrahim ;
Finlay, Jonathan L. ;
Osorio, Diana S. .
CHILDS NERVOUS SYSTEM, 2019, 35 (02) :257-265
[2]  
Amayiri N, 2017, J GLOB ONCOL, V4, DOI 10.1200/JGO.2016.008276
[3]   Improving Pediatric Neuro-Oncology Survival Disparities in the United States-Mexico Border Region: A Cross-Border Initiative Between San Diego, California, and Tijuana, Mexico [J].
Aristizabal, Paula ;
Burns, Luke P. ;
Kumar, Nikhil V. ;
Perdomo, Bianca P. ;
Rivera-Gomez, Rebeca ;
Ornelas, Mario A. ;
Gonda, David ;
Malicki, Denise ;
Thornburg, Courtney D. ;
Roberts, William ;
Levy, Michael L. ;
Crawford, John R. .
JCO GLOBAL ONCOLOGY, 2020, 6 :1791-1802
[4]  
Atun R, 2020, LANCET ONCOL, V21, pE185, DOI 10.1016/S1470-2045(20)30022-X
[5]   Childhood cancer burden: a review of global estimates [J].
Bhakta, Nickhill ;
Force, Lisa M. ;
Allemani, Claudia ;
Atun, Rifat ;
Bray, Freddie ;
Coleman, Michel P. ;
Steliarova-Foucher, Eva ;
Frazier, A. Lindsay ;
Robison, Leslie L. ;
Rodriguez-Galindo, Carlos ;
Fitzmaurice, Christina .
LANCET ONCOLOGY, 2019, 20 (01) :E42-E53
[6]   The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE) [J].
Bhakta, Nickhill ;
Liu, Qi ;
Ness, Kirsten K. ;
Baassiri, Malek ;
Eissa, Hesham ;
Yeo, Frederick ;
Chemaitilly, Wassim ;
Ehrhardt, Matthew J. ;
Bass, Johnnie ;
Bishop, Michael W. ;
Shelton, Kyla ;
Lu, Lu ;
Huang, Sujuan ;
Li, Zhenghong ;
Caron, Eric ;
Lanctot, Jennifer ;
Howell, Carrie ;
Folse, Timothy ;
Joshi, Vijaya ;
Green, Daniel M. ;
Mulrooney, Daniel A. ;
Armstrong, Gregory T. ;
Krull, Kevin R. ;
Brinkman, Tara M. ;
Khan, Raja B. ;
Srivastava, Deo K. ;
Hudson, Melissa M. ;
Yasui, Yutaka ;
Robison, Leslie L. .
LANCET, 2017, 390 (10112) :2569-2582
[7]   Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists? [J].
d'Amati, Antonio ;
Bargiacchi, Lavinia ;
Rossi, Sabrina ;
Carai, Andrea ;
Bertero, Luca ;
Barresi, Valeria ;
Errico, Maria Elena ;
Buccoliero, Anna Maria ;
Asioli, Sofia ;
Marucci, Gianluca ;
Del Baldo, Giada ;
Mastronuzzi, Angela ;
Miele, Evelina ;
D'Antonio, Federica ;
Gessi, Marco ;
Antonelli, Manila ;
Gianno, Francesca .
FRONTIERS IN MOLECULAR NEUROSCIENCE, 2024, 17
[8]  
Gupta S., 2015, Cancer: Disease Control Priorities, V3
[9]   Pediatric Oncology as the Next Global Child Health Priority: The Need for National Childhood Cancer Strategies in Low- and Middle-Income Countries [J].
Gupta, Sumit ;
Rivera-Luna, Roberto ;
Ribeiro, Raul C. ;
Howard, Scott C. .
PLOS MEDICINE, 2014, 11 (06) :1-5
[10]   Comparison of Epidemiology and Outcomes in Neuro-Oncology Between the East and the West: Challenges and Opportunities [J].
Gupta, T. ;
Achari, R. ;
Chatterjee, A. ;
Chen, Z-P ;
Mehta, M. ;
Bouffet, E. ;
Jalali, R. .
CLINICAL ONCOLOGY, 2019, 31 (08) :539-548